AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 18 - (NewsRx.com & NewsRx.net) -- MedImmune, Inc., (MEDI) announced that it has licensed exclusive worldwide rights to human metapneumovirus (hMPV) from ViroNovative, b.v., a private Dutch biotechnology company affiliated with Erasmus University in Rotterdam.
Human metapneumovirus is an infectious respiratory virus recently discovered by researchers at Erasmus Medical Center (Erasmus MC) under the direction of Prof. Dr. Albert Osterhaus. MedImmune intends to use its expertise in pediatric respiratory infectious diseases to develop antibodies and vaccines against hMPV.
"Prof. Dr. Osterhaus' recent discovery of human metapneumovirus is one of those rare eureka moments in medicine," said David M. Mott, MedImmune's CEO. "We are thrilled with the opportunity to work with Prof. Dr. Osterhaus and other researchers in this field to develop products to prevent serious respiratory infections caused by hMPV in young children.
"This new program is an excellent fit with our antibody expertise and our experience with respiratory syncytial virus (RSV). It is also a clear example of the synergy resulting from our recent acquisition of Aviron, now known as MedImmune Vaccines, given the vaccine development expertise in that organization which we can now apply to the hMPV program."
In June 2001, Prof. Dr. Osterhaus and his team published their discovery of hMPV in Nature Medicine.
This previously unknown virus is believed to be a common cause of serious lower respiratory tract infections in young children. It was discovered in cultures from children hospitalized at Erasmus MC with respiratory infections of unknown origin. Subsequently, other laboratories have confirmed the presence of hMPV in North America and Australia. The prevalence of hMPV-specific antibodies in human serum samples suggests that the virus has been infecting humans for at least the last 50 years.
"MedImmune offers a unique opportunity to turn our discovery of human metapneumovirus into products that have the potential to protect ...
Source: HighBeam Research, MedImmune licenses rights to newly discovered human...